{"id":13862,"date":"2026-06-01T17:00:00","date_gmt":"2026-06-01T15:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=884c066e453084070224a322e4b6263f"},"modified":"2026-06-01T17:00:00","modified_gmt":"2026-06-01T15:00:00","slug":"prep-wisdom-viiv-healthcare-launches-new-campaign-to-support-informed-hiv-prevention-choices","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=13862","title":{"rendered":"PrEP Wisdom: ViiV Healthcare Launches New Campaign to Support Informed HIV Prevention Choices"},"content":{"rendered":"<ul class=\"bwlistdisc\">\n<li>\n<i>TV personality Michelle Visage lends her voice to raise awareness about important differences in long-acting injectable PrEP options<\/i><\/li>\n<li>\n<i>More information and resources for people who could benefit from PrEP are available at <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2FGetPrEPWisdom.com&amp;esheet=54544368&amp;newsitemid=20260529456932&amp;lan=en-US&amp;anchor=GetPrEPWisdom.com&amp;index=1&amp;md5=622669d1ceda60abf25bae6fdddbda26\" rel=\"nofollow\" shape=\"rect\">GetPrEPWisdom.com<\/a><\/i><\/li>\n<\/ul><p>DURHAM, N.C.--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced the launch of its <b>PrEP Wisdom<\/b> campaign, designed to empower people to make informed decisions about long-acting injectable (LAI) HIV prevention, beyond the dosing schedules. The campaign features <b>TV personality Michelle Visage<\/b>, a long-time HIV and LGBTQ advocate.<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260529456932\/en\/2819091\/19\/viiv_michelle_brollsoundbite_1_051326_v2.mp4\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260529456932\/en\/2819091\/5\/viiv_michelle_brollsoundbite_1_051326_v2.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260529456932\/en\/2819091\/19\/viiv_michelle_brollsoundbite_1_051326_v2.mp4\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260529456932\/en\/2819091\/21\/viiv_michelle_brollsoundbite_1_051326_v2.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260529456932\/en\/839563\/5\/viiv%2Blogo.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260529456932\/en\/839563\/22\/viiv%2Blogo.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260529456932\/en\/839563\/5\/viiv%2Blogo.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260529456932\/en\/839563\/21\/viiv%2Blogo.jpg\" \/><\/a><p>\nApproximately 2.2 million people in the US could benefit from pre-exposure prophylaxis, also known as PrEP, yet only about 25% are currently utilizing it.<sup>1,2 <\/sup>PrEP, when used as prescribed, can significantly reduce the chance of getting HIV through sex. It doesn\u2019t protect against sexually transmitted infections (STIs), however, so people should still practice safer sex to reduce their risk of STIs.<\/p><p>\nSince the introduction of daily oral PrEP more than a decade ago, newer options like long-acting injectable PrEP have become available, offering flexibility for individuals to choose the approach that works best for them. Yet, factors such as stigma and lack of open dialogue between patients and providers can hinder honest conversations around prevention options. Learning more about the differences in LAI PrEP options and encouraging individuals to have deeper conversations with their doctors\u2014getting \u2018PrEP wise\u2019\u2014is at the core of this new campaign.<\/p><p>\nReinforcing the importance of patient education and open dialogue with healthcare providers, Visage highlighted the need for LAI HIV prevention options that are tailored to individual preferences and routines.<\/p><p>\n\u201cHIV prevention is not one-size-fits-all, and injectable PrEP options are not the same. Everyone\u2019s day-to-day life, needs, and comfort level are different,\u201d said Visage. \u201cReal empowerment around sexual health and well-being includes having \u2018PrEP Wisdom\u2019 and knowing about the available options, including the differences in long-acting injectable PrEP beyond the dosing schedule, so you can work with your doctor to determine what may work best for you.\u201d<\/p><p>\nViiV Healthcare has been focused on HIV since the beginning of the epidemic more than 40 years ago. From developing the first ever HIV treatment to pioneering the first LAIs for PrEP and treatment, ViiV Healthcare scientists have helped bring significant advancements to the HIV community. Now, with more LAI PrEP choices available, ViiV Healthcare is empowering individuals to understand the distinct characteristics and important considerations of each option, helping ensure they arrive at their doctor's appointments prepared for an informed discussion about LAI PrEP.<\/p><p>\n\u201cHIV prevention options have come a long way over the past decade,\u201d said <b>Nithya Srinivasan, Vice President of US Marketing at ViiV Healthcare<\/b>. \u201cOur goal now is to encourage people who could benefit from PrEP to understand their long-acting injectable options\u2014including knowing what to ask their doctor, such as where on their body the injection is administered, whether other medicines or supplements they are taking may interact with their PrEP medicine, and what to expect before, during, and after their injection\u2014so they can make more informed decisions about their care. 'PrEP Wisdom' aims to foster that dialogue between patients and doctors and equip people with the information they need to navigate their PrEP journey confidently.\u201d<\/p><p>\nTo learn more about LAI PrEP and get \u2018PrEP Wise,\u2019 visit <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fgetprepwisdom.com%2F&amp;esheet=54544368&amp;newsitemid=20260529456932&amp;lan=en-US&amp;anchor=GetPrEPWisdom.com&amp;index=2&amp;md5=9351088277aca5a4766ab26765794a87\" rel=\"nofollow\" shape=\"rect\"><b>GetPrEPWisdom.com<\/b><\/a>.<\/p><p>\n<b>About ViiV Healthcare\n<br\/><\/b>ViiV Healthcare is a global specialist HIV company established in November 2009 with GSK (LSE: GSK) and Shionogi as current shareholders. The company is dedicated to delivering advances in treatment and care for people living with HIV and for people who could benefit from HIV prevention. ViiV Healthcare\u2019s aims are to take a deeper and broader interest in HIV and AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV.<\/p><p>\n<b>About Michelle Visage\n<br\/><\/b>Multiple award winning, internationally renowned television personality, radio show host, podcast host, platinum-selling recording artist and author, Michelle Visage has made a name for herself in the entertainment industry, across multiple mediums for the past three decades.<\/p><p>\nVisage initially rose to fame as a member of the girl group Seduction (A&amp;M Records) in the early 1990s. Today, Visage can be seen all over the world as head judge on the multiple Emmy Award winning show, \"RuPaul\u2019s Drag Race.\" In 2026, Visage partnered with ViiV Healthcare as a paid spokesperson for its PrEP Wisdom campaign to help raise awareness of long-acting injectable PrEP options.<\/p><p>\n<b>About GSK\n<br\/><\/b>GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fgsk.com&amp;esheet=54544368&amp;newsitemid=20260529456932&amp;lan=en-US&amp;anchor=gsk.com&amp;index=3&amp;md5=449f1a56cd6237e11071f10b557c694a\" rel=\"nofollow\" shape=\"rect\">gsk.com<\/a>.<\/p><p>\n<b>Cautionary statement regarding forward-looking statements\n<br\/><\/b>GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the \u201cRisk Factors\u201d section in GSK\u2019s Annual Report on Form 20-F for 2024, and GSK\u2019s Q1 Results for 2026.<\/p><table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth60\">\n<tr>\n<td class=\"bwwidth50\" colspan=\"2\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Registered in England &amp; Wales:<\/b><\/p><\/td><\/tr>\n<tr>\n<td class=\"bwwidth50\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nGSK plc\n<br\/>No. 3888792<\/p><\/td><td class=\"bwvertalignt bwpadl0 bwwidth50\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nViiV Healthcare Limited\n<br\/>No. 06876960<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwpadl0 bwwidth50\" colspan=\"1\" rowspan=\"1\"\/>\n<td class=\"bwpadl0 bwwidth50\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth50\" colspan=\"2\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Registered Office:<\/b><\/p><\/td><\/tr>\n<tr>\n<td class=\"bwwidth50\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n79 New Oxford Street\n<br\/>London\n<br\/>WC1A 1DG<\/p><\/td><td class=\"bwvertalignt bwpadl0 bwwidth50\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nViiV Healthcare Limited\n<br\/>GSK Medicines Research Centre\n<br\/>Gunnels Wood Road, Stevenage<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwpadl0 bwwidth50\" colspan=\"1\" rowspan=\"1\"\/>\n<td class=\"bwpadl0 bwwidth50\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nUnited Kingdom<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwwidth50\" colspan=\"1\" rowspan=\"1\"\/>\n<td class=\"bwvertalignt bwpadl0 bwwidth50\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nSG1 2NY<\/p><\/td><\/tr>\n<\/table><table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwpadl0 bwwidth100\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>References:<\/b><\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth100\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n____________________<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwpadl0 bwwidth100\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n1. Estimating the population need for preexposure prophylaxis for HIV in the United States \u2013 sciencedirect.com. Science Direct. Published June 2025. Accessed May 8, 2026. <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.sciencedirect.com%2Fscience%2Farticle%2Fabs%2Fpii%2FS1047279725000900%3Fvia%253Dihub&amp;esheet=54544368&amp;newsitemid=20260529456932&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.sciencedirect.com%2Fscience%2Farticle%2Fabs%2Fpii%2FS1047279725000900%3Fvia%253Dihub&amp;index=4&amp;md5=97d56456b026f429e242f37d292780f9\" rel=\"nofollow\" shape=\"rect\">https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S1047279725000900?via%3Dihub<\/a><\/p><\/td><\/tr>\n<tr>\n<td class=\"bwpadl0 bwwidth100\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n2. A Decade of HIV Preexposure Prophylaxis (PrEP): Overcoming Access Barriers in the United States Through Expanded Delivery \u2013 National Library of Medicine, Public Health Reports. Published November 30, 2023. Access May 18, 2026. <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC11284973%2F&amp;esheet=54544368&amp;newsitemid=20260529456932&amp;lan=en-US&amp;anchor=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC11284973%2F&amp;index=5&amp;md5=af144372c18a6e87689eca345e982741\" rel=\"nofollow\" shape=\"rect\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11284973\/<\/a><\/p><\/td><\/tr>\n<\/table><p>\n\u00a0<\/p><br\/> <b>Contacts<\/b> <br\/><p>\n<b>ViiV Healthcare enquiries:<\/b><br\/>Media:\n<br\/>Robin Gaitens\n<br\/>+1 984 459 0035\n<br\/>(North Carolina)<\/p><p>\nBithiah Lafontant\n<br\/>+1 984 239 4915\n<br\/>(North Carolina)<\/p><p>\n<b>GSK enquiries:\n<br\/><\/b>Media:\n<br\/>Tim Foley\n<br\/>+44 (0) 20 8047 5502\n<br\/>(London)<\/p><p>\nSarah Clements\n<br\/>+44 (0) 20 8047 5502\n<br\/>(London)<\/p><p>\nKathleen Quinn\n<br\/>+1 202 603 5003\n<br\/>(Washington DC)<\/p><p>\nAlison Hunt\n<br\/>+1 540 742 3391\n<br\/>(Washington DC)<\/p>","protected":false},"excerpt":{"rendered":"<p>TV personality Michelle Visage lends her voice to raise awareness about important differences in long-acting injectable PrEP options<\/p>\n<p>More information and resources for people who could benefit from PrEP are available at GetPrEPWisdom.com<br \/>\nDURHAM, N.C&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-13862","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/13862","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=13862"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/13862\/revisions"}],"predecessor-version":[{"id":13863,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/13862\/revisions\/13863"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=13862"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=13862"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=13862"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}